FRA
CRL icon

Front Row Advisors’s Charles River Laboratories CRL Stock Holding History

Front Row Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-170
Closed -$35.1K – 585
2024
Q2 		$35.1K Sell
170
-2
-1% -$453 0.01% 312
2024
Q1 		$46.6K Buy
+172
New +$41.1K 0.02% 270
2023
Q4 		– Sell
-178
Closed -$34.9K – 554
2023
Q3 		$34.9K Buy
178
+1
+0.6% +$205 0.02% 278
2023
Q2 		$37K Sell
177
-5
-3% -$995 0.02% 275
2023
Q1 		$37K Sell
182
-2
-1% -$453 0.02% 273
2022
Q4 		$40K Hold
184
– – 0.02% 261
2022
Q3 		$36K Sell
184
-1
-0.5% -$216 0.02% 271
2022
Q2 		$40K Hold
185
– – 0.02% 267
2022
Q1 		$53K Sell
185
-1
-0.5% -$308 0.02% 256
2021
Q4 		$70K Sell
186
-23
-11% -$8.94K 0.03% 232
2021
Q3 		$86K Hold
209
– – 0.04% 212
2021
Q2 		$88K Sell
209
-44
-17% -$14.7K 0.04% 209
2021
Q1 		$73K Sell
253
-5
-2% -$1.39K 0.04% 213
2020
Q4 		$64K Hold
258
– – 0.03% 225
2020
Q3 		$59K Sell
258
-2
-0.8% -$415 0.03% 229
2020
Q2 		$45K Buy
260
+47
+22% +$7.5K 0.03% 231
2020
Q1 		$31K Hold
213
– – 0.02% 268
2019
Q4 		$33K Hold
213
– – 0.02% 247
2019
Q3 		$28K Hold
213
– – 0.02% 260
2019
Q2 		$30K Hold
213
– – 0.02% 258
2019
Q1 		$31K Sell
213
-2
-0.9% -$263 0.02% 246
2018
Q4 		$24K Hold
215
– – 0.02% 261
2018
Q3 		$24K Sell
215
-44
-17% -$5.43K 0.02% 279
2018
Q2 		$32K Hold
259
– – 0.02% 269
2018
Q1 		$28K Sell
259
-6
-2% -$647 0.02% 287
2017
Q4 		$29K Buy
+265
New +$28.8K 0.02% 292

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Front Row Advisors's CRL Position: Q3 2024 in Review

Front Row Advisors sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 170 shares — an estimated $35.1K sold.

Front Row Advisors first reported a position in CRL in Q4 2017 and held it in 26 quarters. The position peaked at $88K in Q2 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Front Row Advisors reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 170 Charles River Laboratories shares in Q3 2024, an estimated $35.1K.
  • Front Row Advisors first reported a position in Charles River Laboratories in Q4 2017 and held it in 26 quarters.
  • Front Row Advisors's Charles River Laboratories position peaked at $88K in Q2 2021.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.